Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Danielle A. Sliter Clear advanced filters

  • The PINK1 ubiquitin kinase is shown to recruit the two autophagy receptors NDP52 and OPTN to mitochondria to activate mitophagy directly, independently of the ubiquitin ligase parkin; once recruited to mitochondria, NDP52 and OPTN recruit autophagy initiation components, and parkin may amplify the phospho-ubiquitin signal generated by PINK1, resulting in robust autophagy induction.

    • Michael Lazarou
    • Danielle A. Sliter
    • Richard J. Youle
    Research
    Nature
    Volume: 524, P: 309-314

  • Mitophagy selectively disposes of dysfunctional mitochondria and defects in this process lead to a variety of mitochondrial diseases. Here the authors report that the mitochondrial protein PGAM5 is required for the stabilization of mitophagy-inducing protein PINK1, and that mice deficient for the gene coding for PGAM5 show signs of neurodegeneration.

    • Wei Lu
    • Senthilkumar S. Karuppagounder
    • Michael Lenardo
    Research
    Nature Communications
    Volume: 5, P: 1-11

  • Mitophagy is the elimination of damaged mitochondria by the autophagosome regulated by the ubiquitin ligase, parkin and the kinase PINK1; a genome-wide RNAi screen with high-content microscopy has identified new genes that have an upstream role in parkin translocation to the mitochondria.

    • Samuel A. Hasson
    • Lesley A. Kane
    • Richard J. Youle
    Research
    Nature
    Volume: 504, P: 291-295

  • With its novel adeno-associated virus discovery platform, Latus Bio is addressing problems associated with high-dose gene therapy for central nervous system diseases, aiming to usher in a new era of safer, more effective, and lower cost treatments.

    • Latus Bio
    Advertorial
    Biopharma Dealmakers